Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02973100 · ClinicalTrials.gov registry record · Phase 2
A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy
A Phase 2 study of Type 2 Diabetes, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 318
- Enrollment target
- 20
- Study locations
NCT02973100: Completed Phase 2 study of Type 2 Diabetes, sponsored by Eli Lilly and Company.
NCT02973100 is a Phase 2 study of Type 2 Diabetes that has completed, run by Eli Lilly and Company. The registered enrollment target is 318 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02973100, a Phase 2 study of Type 2 Diabetes, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 318 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.
Primary Outcome
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline as a covariate, pooled country, treatment, time, treatment\*time as fixed effects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dulaglutide
Study Locations (20)
California
- Parexel Early Phase Unit at Glendale - Glendale
- Marin Endocrine Associates - Greenbrae
- National Research Institute - Huntington Park
- National Research Institute - Los Angeles
- Catalina Research Institute, LLC - Montclair
- Artemis Institute for Clinical Research - San Diego
- Encompass Clinical Research - Spring Valley Lake
- University Clinical Investigators, Inc. - Tustin
- Infosphere - Van Nuys
- Diablo Clinical Research - Walnut Creek
Florida
- Axes Medical Research, LLC - Cooper City
- Clinical Research of South Florida - Coral Gables
- East Coast Institute For Research - Jacksonville
- New Horizon Research Center - Miami
- Suncoast Research Group, LLC - Miami Lakes
- Palm Harbor Medical Associates - Palm Harbor
Connecticut
- Chase Medical Research, LLC - Waterbury
Georgia
- In-Quest Medical Research, LLC - Norcross - Norcross
Hawaii
- East West Medical Institute - Honolulu
Idaho
- Elite Cilnical Trials LLLP - Blackfoot
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2016-12 |
| Est. Completion | 2017-08-14 |
| Phase | Phase 2 |
What the finished NCT02973100 record still lists
NCT02973100 is an interventional study that assigns participants to a tested intervention. The registered 318 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02973100 names 20 study sites across 6 states, led by California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02973100 about?
NCT02973100 is a clinical study titled "A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy". The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.
What is the current status of trial NCT02973100?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 318 participants. The study started on 2016-12. Estimated completion is 2017-08-14.
What conditions does trial NCT02973100 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT02973100?
The interventions under investigation include: Placebo (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT02973100?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02973100 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02973100's enrollment target sits among peer trials
318 64th of 327 higher than 264 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Renal Mechanism of SGLT2 Inhibition
RECRUITING · Phase 2
-
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
RECRUITING · Phase 2
-
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
RECRUITING · Phase 2
-
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
RECRUITING · Phase 2
-
NAD Augmentation in Diabetes Kidney Disease
RECRUITING · Phase 2
-
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05488340 · 318 participants · Phase 2
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
- NCT05675735 · 318 participants · NA
Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder
- NCT05895786 · 318 participants · Phase 3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- NCT06051617 · 318 participants · Phase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia